Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 10001, USA.
Semin Respir Crit Care Med. 2011 Aug;32(4):527-40. doi: 10.1055/s-0031-1283289. Epub 2011 Aug 19.
Viral respiratory infections cause significant morbidity and mortality in infants and young children as well as in at-risk adults and the elderly. Although many viral pathogens are capable of causing respiratory disease, vaccine development has to focus on a limited number of pathogens, such as those that commonly cause serious lower respiratory illness (LRI). Whereas influenza virus vaccines have been available for some time (see the review by Clark and Lynch in this issue), vaccines against other medically important viruses such as respiratory syncytial virus (RSV), the parainfluenza viruses (PIVs), and metapneumovirus (MPVs) are not available. This review aims to provide a brief update on investigational vaccines against RSV, the PIVs, and MPV that have been evaluated in clinical trials or are currently in clinical development.
病毒性呼吸道感染可导致婴幼儿以及高危成年人和老年人发生重大发病率和死亡率。尽管许多病毒病原体能够引起呼吸道疾病，但疫苗的开发必须集中在少数病原体上，例如那些常见的严重下呼吸道疾病（LRI）病原体。虽然流感病毒疫苗已经问世一段时间（请参阅本期 Clark 和 Lynch 的综述），但针对其他重要的呼吸道病毒如呼吸道合胞病毒（RSV）、副流感病毒（PIVs）和肺炎支原体（MPVs）的疫苗尚未问世。本综述旨在简要介绍 RSV、PIV 和 MPV 的研究性疫苗的最新情况，这些疫苗已在临床试验中进行了评估或正在临床开发中。
